«KSI Ventures» LTD is a Russian investment company focused on investing in projects in the field of living systems at the seed stage, as well as microfinance and the acceleration of promising projects. «KSI Ventures» is a member of the biopharmaceutical cluster "Northern" - association of the leading enterprises of the Russian pharmaceutical, biotech and medical industries, research institutes, hospitals and small innovative companies at the Moscow Institute of physics and technology (MIPT).
The main objectives of the company is to development of breakthrough medicines and medical devices.
Since 2014 "KSI Ventures" has invested in 16 start-ups, and in 2015, as the managing partner of «Seed Fund» in the field of living systems, created in conjunction with the RVC Seed Fund in the form of investment partnership.
"KSI Ventures" is considering projects in the following directions:
- Medical equipment
- Cellular and genomic technology
- Agricultural biotechnology
- The creation of new materials
"KSI Ventures" has experience acceleration companies - from zero to the first sale, as well as access to a wide pool of participants of Biopharmcluster "Northern".
OOO "KSI ventures" and the RVC seed Fund (RVC SF) and created MIKROFOND in the form of an investment partnership — Seed Fund in the field of living systems.
The RVC seed Fund (RVC SF) and "KSI ventures" announced the creation of MIKROFOND in the form of an investment partnership — Seed Fund in the field of living systems. The Fund will amount to 33,4 million rubles, of which 25 million rubles are invested by the RVC seed Fund, and 8.4 million rubles — managing partner of the Fund — "KSI ventures". The investment period is 2 years. It is anticipated additional capitalization of the Fund before the end of this period. The Fund will invest in early-stage projects in the field of living systems: biomedical, pharmaceutical, cellular, genomic, agrobio - and Neurotechnology, as well as bioengineering. Interest for the Fund are the developers of import-substituting products and projects at the intersection of bio and IT technologies, new materials and instrumentation, as well as technologies that have the potential for commercialization in the global market.